Page last updated: 2024-09-03

imatinib mesylate and Hypopharyngeal Neoplasms

imatinib mesylate has been researched along with Hypopharyngeal Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agarwal, JP; Banavali, S; Budrukkar, A; Chatturvedi, P; D'Cruz, A; Laskar, SG; Murthy, V; Muttagi, S; Shahid, T	1
Baer, MR; Bowman, MJ; Liu, W; Morgan, J; Oseroff, AR; Pandey, RA; Pera, P; Zheng, X	1

Other Studies

2 other study(ies) available for imatinib mesylate and Hypopharyngeal Neoplasms

Article	Year
Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia. The British journal of oral & maxillofacial surgery, 2012, Volume: 50, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Follow-Up Studies; Gingival Neoplasms; Humans; Hydroxyurea; Hypopharyngeal Neoplasms; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Neoplasms; Neoplasms, Second Primary; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tongue Neoplasms	2012
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Humans; Hypopharyngeal Neoplasms; Imatinib Mesylate; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2007

Article

Year

Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.

The British journal of oral & maxillofacial surgery, 2012, Volume: 50, Issue:6

Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Follow-Up Studies; Gingival Neoplasms; Humans; Hydroxyurea; Hypopharyngeal Neoplasms; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Neoplasms; Neoplasms, Second Primary; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tongue Neoplasms

2012

The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8

Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Humans; Hypopharyngeal Neoplasms; Imatinib Mesylate; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2007